论文部分内容阅读
目的 :探讨胸腺肽对慢性乙型肝炎的治疗作用及其机制。方法 :按诊断标准选择轻度慢性乙型肝炎77例 ,随机分为胸腺肽治疗组 (47例 )和对照组 (30例 ) ,观察胸腺肽对慢性乙型肝炎患者ALT和乙肝标记物的作用 ,及其免疫指标的变化和相互关系。结果 :胸腺肽治疗组ALT复常的时间较对照组明显缩短 ,促进HBeAg的阴转 ,抑制HBV的复制 (P <0 .0 5 ) ,提高细胞免疫应答能力 ,恢复机体的免疫平衡状态 (P <0 .0 5 )。结论 :胸腺肽能促进慢性乙型肝炎ALT的复常 ,抑制HBV的复制。
Objective: To investigate the therapeutic effect of thymosin on chronic hepatitis B and its mechanism. Methods: According to diagnostic criteria, 77 patients with mild chronic hepatitis B were randomly divided into thymosin treatment group (n = 47) and control group (n = 30). The effect of thymosin on ALT and hepatitis B markers in patients with chronic hepatitis B Changes in their immune parameters and their relationship. Results: Compared with the control group, thymosin treatment group was significantly shorter than the control group, promoting the negative conversion of HBeAg, inhibiting HBV replication (P <0.05), enhancing cellular immune response and restoring the immune balance (P < 0 .0 5). Conclusion: Thymosin can promote the normalization of ALT in chronic hepatitis B and inhibit the replication of HBV.